People featured on this page are taking BRIUMVI and have been compensated by TG Therapeutics for their time.
*Based on combined clinical research across RMS indication of BRIUMVI initiated in 2016. BRIUMVI was approved by the FDA in 2022.
†After the original BRIUMVI studies, people continued to participate for a longer evaluation, where they were all treated with BRIUMVI. This study is ongoing.
‡“Highest-volume U.S. MS centers” are defined as centers ranked by total MS patient volume. A center was considered to have prescribed BRIUMVI if claims data showed at least one patient received BRIUMVI during the analysis period.
§As of March 2026, more than 22,000 people in the U.S. have been prescribed BRIUMVI.
†After the original BRIUMVI studies, people continued to participate for a longer evaluation, where they were all treated with BRIUMVI. This study is ongoing.
‡“Highest-volume U.S. MS centers” are defined as centers ranked by total MS patient volume. A center was considered to have prescribed BRIUMVI if claims data showed at least one patient received BRIUMVI during the analysis period.
§As of March 2026, more than 22,000 people in the U.S. have been prescribed BRIUMVI.
∥Following the starting dose.
Find out why people are choosing BRIUMVI
Brittany,
a schoolteacher, shares her diagnosis-to-treatment story with BRIUMVI.
Alex,
a dad, real estate agent, and fitness trainer, shares his perspective on why BRIUMVI was the right choice for him.
Meaghan,
a dog mom and outdoors and fitness enthusiast, shares her perspective on researching treatment options and choosing BRIUMVI.
Stay in the Know
Join us for a Multiple Sclerosis (MS) educational event near you
Sign up to receive the latest updates and resources for BRIUMVI
Hear from real people with RMS who made the decision with their healthcare provider to BRING ON BRIUMVI